Journal Logo

CE Connection

New Drugs 2020, part 2

Author Information
doi: 10.1097/01.NURSE.0000662860.74416.d7
  • Free

INSTRUCTIONS New Drugs 2020, part 2

TEST INSTRUCTIONS

  • Read the article. The test for this CE activity is to be taken online at www.nursingcenter.com/CE/nursing.
  • You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
  • There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact Lippincott Professional Development: 1-800-787-8985.
  • Registration deadline is March 4, 2022.

PROVIDER ACCREDITATION

Lippincott Professional Development will award 1.5 contact hours and 1.5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223.

Payment: The registration fee for this test is $17.95.

New Drugs 2020, part 2

GENERAL PURPOSE: To provide information about seven new drugs recently approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe indications for seven newly approved drugs. 2. Identify nursing implications for these new drugs.

  1. Lefamulin is indicated to treat adults with community-acquired bacterial pneumonia caused by certain susceptible microorganisms, including
    1. Pseudomonas aeruginosa.
    2. Enterobacter cloacae.
    3. Streptococcus pneumoniae.
  2. Which is an adverse cardiac effect of lefamulin?
    1. left bundle branch block
    2. QT interval prolongation
    3. Mobitz type I second-degree AV block
  3. What electrolyte abnormality can occur from I.V. administration of lefamulin?
    1. hypokalemia
    2. hyponatremia
    3. hypocalcemia
  4. The bioavailability of oral lefamulin may be reduced if patients take it with a
    1. high-fat meal.
    2. high-carbohydrate meal.
    3. high-protein meal.
  5. Rifamycin is indicated for treatment of
    1. rheumatoid arthritis.
    2. psoriasis.
    3. travelers' diarrhea.
  6. The most common adverse reactions to rifamycin include
    1. headache.
    2. hepatic enzyme elevation.
    3. insomnia.
  7. Warn patients not to take rifamycin with
    1. quinidine.
    2. aspirin.
    3. alcohol.
  8. Which statement about risankizumab is correct?
    1. It is administered orally.
    2. It is a monoclonal antibody.
    3. It selectively binds to interleukin IL-17A.
  9. A possible adverse reaction to risankizumab is
    1. constipation.
    2. liver injury.
    3. tinea infections.
  10. Upadacitinib is indicated for adults with moderately-to-severely active
    1. psoriasis.
    2. rheumatoid arthritis.
    3. relapsing forms of MS.
  11. Use of upadacitinib increases the risk of
    1. third-degree AV block.
    2. pulmonary embolism.
    3. torsades de pointes.
  12. Monitor patients taking upadacitinib for elevated levels of serum
    1. lipids.
    2. antidiuretic hormone.
    3. glucose.
  13. What should patients avoid while they are taking upadacitinib?
    1. live vaccines
    2. cigarette smoking
    3. digitalis
  14. Because of the risk of cardiac complications, siponimod generally should not be initiated in patients who are concurrently treated with
    1. clopidogrel.
    2. atorvastatin.
    3. verapamil.
  15. A potential adverse reaction to siponimod is
    1. hypertension.
    2. deep vein thrombosis.
    3. tinnitus.
  16. Amifampridine is the first drug approved to treat adults with
    1. Lambert-Eaton myasthenic syndrome.
    2. Allan-Herndon-Dudley syndrome.
    3. Holmes-Adie syndrome.
  17. The most important concern with amifampridine is a risk of
    1. disseminated intravascular coagulation.
    2. malignancies.
    3. seizures.
  18. Bremelanotide administration may cause a transient increase in
    1. BP.
    2. heart rate.
    3. body temperature.
Wolters Kluwer Health, Inc. All rights reserved